7 results on '"Farmakis, Ioannis"'
Search Results
2. Predisposing factors for admission to intensive care units of patients with COVID-19 infection-Results of the German nationwide inpatient sample.
- Author
-
Keller K, Farmakis IT, Valerio L, Koelmel S, Wild J, Barco S, Schmidt FP, Espinola-Klein C, Konstantinides S, Münzel T, Sagoschen I, and Hobohm L
- Subjects
- Humans, Male, Female, Inpatients, COVID-19 Testing, Hospital Mortality, Pandemics, Hospitalization, Risk Factors, Intensive Care Units, COVID-19, Cardiovascular Diseases
- Abstract
Background: Intensive care units (ICU) capacities are one of the most critical determinants in health-care management of the COVID-19 pandemic. Therefore, we aimed to analyze the ICU-admission and case-fatality rate as well as characteristics and outcomes of patient admitted to ICU in order to identify predictors and associated conditions for worsening and case-fatality in this critical ill patient-group., Methods: We used the German nationwide inpatient sample to analyze all hospitalized patients with confirmed COVID-19 diagnosis in Germany between January and December 2020. All hospitalized patients with confirmed COVID-19 infection during the year 2020 were included in the present study and were stratified according ICU-admission., Results: Overall, 176,137 hospitalizations of patients with COVID-19-infection (52.3% males; 53.6% aged ≥70 years) were reported in Germany during 2020. Among them, 27,053 (15.4%) were treated in ICU. COVID-19-patients treated on ICU were younger [70.0 (interquartile range (IQR) 59.0-79.0) vs. 72.0 (IQR 55.0-82.0) years, P < 0.001], more often males (66.3 vs. 48.8%, P < 0.001), had more frequently cardiovascular diseases (CVD) and cardiovascular risk-factors with increased in-hospital case-fatality (38.4 vs. 14.2%, P < 0.001). ICU-admission was independently associated with in-hospital death [OR 5.49 (95% CI 5.30-5.68), P < 0.001]. Male sex [OR 1.96 (95% CI 1.90-2.01), P < 0.001], obesity [OR 2.20 (95% CI 2.10-2.31), P < 0.001], diabetes mellitus [OR 1.48 (95% CI 1.44-1.53), P < 0.001], atrial fibrillation/flutter [OR 1.57 (95% CI 1.51-1.62), P < 0.001], and heart failure [OR 1.72 (95% CI 1.66-1.78), P < 0.001] were independently associated with ICU-admission., Conclusion: During 2020, 15.4% of the hospitalized COVID-19-patients were treated on ICUs with high case-fatality. Male sex, CVD and cardiovascular risk-factors were independent risk-factors for ICU admission., Competing Interests: SB received lecture/consultant fees from Bayer HealthCare, Concept Medical, BTG Pharmaceuticals, INARI, Boston Scientific, and LeoPharma; institutional grants from Boston Scientific, Bentley, Bayer HealthCare, INARI, Medtronic, Concept Medical, Bard, and Sanofi; and economical support for travel/congress costs from Daiichi Sankyo, BTG Pharmaceuticals, and Bayer HealthCare, outside the submitted work. CE-K reports having from Amarin Germany, Amgen GmbH, Bayer Vital, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, MSD Sharp & Dohme, Novartis Pharma, Pfizer Pharma GmbH, and Sanofi-Aventis GmbH. SKon reports institutional grants and personal lecture/advisory fees from Bayer AG, Daiichi Sankyo, and Boston Scientific; institutional grants from Inari Medical; and personal lecture/advisory fees from MSD and Bristol Myers Squibb/Pfizer. TM is PI of the DZHK (German Center for Cardiovascular Research), Partner Site Rhine-Main, Mainz, Germany. LH received lecture/consultant fees from MSD and Actelion, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Keller, Farmakis, Valerio, Koelmel, Wild, Barco, Schmidt, Espinola-Klein, Konstantinides, Münzel, Sagoschen and Hobohm.)
- Published
- 2023
- Full Text
- View/download PDF
3. COVID-19 infection and its impact on case fatality in patients with pulmonary embolism.
- Author
-
Hobohm L, Sagoschen I, Barco S, Farmakis IT, Fedeli U, Koelmel S, Gori T, Espinola-Klein C, Münzel T, Konstantinides S, and Keller K
- Subjects
- Humans, Hospital Mortality, Inpatients, Prognosis, COVID-19 complications, Pulmonary Embolism complications
- Abstract
Background: Although a high prevalence of pulmonary embolism (PE) has been reported in association with coronavirus disease 2019 (COVID-19) in critically ill patients, nationwide data on the outcome of hospitalised patients with COVID-19 and PE are still limited. Thus, we investigated seasonal trends and predictors of in-hospital death in patients with COVID-19 and PE in Germany., Methods: We used a German nationwide inpatient sample to analyse data on hospitalisations among COVID-19 patients with and without PE during 2020, and to detect changes in PE prevalence and case fatality in comparison with 2019., Results: We analysed 176 137 COVID-19 hospitalisations in 2020; PE was recorded in 1.9% (n=3362) of discharge certificates. Almost one-third of patients with COVID-19 and PE died during the in-hospital course (28.7%) compared with COVID-19 patients without PE (17.7%). Between 2019 and 2020, numbers of PE-related hospitalisations were largely unchanged (98 485 versus 97 718), whereas the case fatality rate of PE increased slightly in 2020 (from 12.7% to 13.1%; p<0.001). Differences in case fatality were found between PE patients with and without COVID-19 in 2020 (28.7% versus 12.5%; p<0.001), corresponding to a 3.1-fold increased risk of PE-related death (OR 3.16, 95% CI 2.91-3.42; p<0.001) in the presence of COVID-19., Conclusions: In Germany, the prevalence of PE events during hospitalisations was similar in 2019 and 2020. However, the fatality rate among patients with both COVID-19 and PE was substantially higher than that in those with only one of these diseases, suggesting a life-threatening additive prognostic impact of the COVID-19-PE combination., Competing Interests: Conflict of interest: L. Hobohm reports lecture/consultant fees from MSD and Actelion, outside the submitted work. I. Sagoschen reports lecture/consultant fees from Hamilton Medical and Novalung, outside the submitted work. S. Barco reports lecture/consultant fees from Bayer HealthCare, Concept Medical, BTG Pharmaceuticals, INARI, Boston Scientific and LeoPharma; institutional grants from Boston Scientific, Bentley, Bayer HealthCare, INARI, Medtronic, Concept Medical, Bard and Sanofi; and financial support for travel/congress costs from Daiichi Sankyo, BTG Pharmaceuticals and Bayer HealthCare, outside the submitted work. I.T. Farmakis reports no conflict of interests. U. Fedeli reports no conflict of interests. S. Koelmel reports no conflict of interests. T. Gori reports consultancy and lecture honoraria from Abbott Vascular and Boston Scientific. C. Espinola-Klein reports lecture fees and/or travel costs from Amarin Germany, Amgen GmbH, Bayer Vital, Boehringer Ingelheim, BMS, Daiichi Sankyo, Leo Pharma, MSD, Novartis Pharma, Pfizer Pharma GmbH and Sanofi-Aventis GmbH. T. Münzel is PI of the DZHK (German Center for Cardiovascular Research), Partner Site Rhine Main, Mainz, Germany. S. Konstantinides reports institutional grants and personal lecture/advisory fees from Bayer AG, Daiichi Sankyo, Boehringer Ingelheim and Boston Scientific; institutional grants from Inari Medical and Actelion; and personal lecture/advisory fees from MSD and BMS/Pfizer. K. Keller reports no conflict of interests., (Copyright ©The authors 2023.)
- Published
- 2023
- Full Text
- View/download PDF
4. Management of COVID-19 in Patients with Pulmonary Arterial Hypertension.
- Author
-
Farmakis IT and Giannakoulas G
- Subjects
- Humans, Pandemics, Pulmonary Arterial Hypertension etiology, Pulmonary Arterial Hypertension therapy, COVID-19 complications, Telemedicine, Hypertension, Pulmonary etiology, Hypertension, Pulmonary therapy
- Abstract
In this review, we discuss the evidence regarding the course and management of COVID-19 in patients with pulmonary arterial hypertension (PAH), the challenges in PAH management during the pandemic and, lastly, the long-term complications of COVID-19 in relation to pulmonary vascular disease. The inherent PAH disease characteristics, as well as age, comorbidities, and the patient's functional status act synergistically to define the prognosis of COVID-19 in patients with PAH. Management of COVID-19 should follow the general guidelines, while PAH-targeted therapies should be continued. The pandemic has caused a shift toward telemedicine in the chronic care of patients with PAH. Whether COVID-19 could predispose to the development of chronic pulmonary hypertension is a subject of future investigation., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
5. Annual Mortality Related to Pulmonary Embolism in the U.S. Before and During the COVID-19 Pandemic.
- Author
-
Farmakis IT, Valerio L, Bikdeli B, Connors JM, Giannakoulas G, Goldhaber SZ, Hobohm L, Hunt BJ, Keller K, Spyropoulos AC, and Barco S
- Subjects
- Anticoagulants, Humans, Pandemics, COVID-19, Pulmonary Embolism epidemiology
- Published
- 2022
- Full Text
- View/download PDF
6. Deaths related to pulmonary embolism and cardiovascular events before and during the 2020 COVID-19 pandemic: An epidemiological analysis of data from an Italian high-risk area.
- Author
-
Voci D, Fedeli U, Farmakis IT, Hobohm L, Keller K, Valerio L, Schievano E, Barbiellini Amidei C, Konstantinides SV, Kucher N, and Barco S
- Subjects
- Female, Humans, International Classification of Diseases, Italy epidemiology, Male, Pandemics, COVID-19 complications, Pulmonary Embolism epidemiology
- Abstract
Background: Pulmonary embolism is a known complication of coronavirus disease 2019 (COVID-19). Epidemiological population data focusing on pulmonary embolism-related mortality is limited., Methods: Veneto is a region in Northern Italy counting 4,879,133 inhabitants in 2020. All ICD-10 codes from death certificates (1st January 2018 to 31st December 2020) were examined. Comparisons were made between 2020 (COVID-19 outbreak) and the average of the two-year period 2018-2019. All-cause, COVID-19-related and the following cardiovascular deaths have been studied: pulmonary embolism, hypertensive disease, ischemic heart disease, atrial fibrillation/flutter, and cerebrovascular diseases., Results: In 2020, a total of 56,412 deaths were recorded, corresponding to a 16% (n = 7806) increase compared to the period 2018-2019. The relative percentage increase during the so-called first and second waves was 19% and 44%, respectively. Of 7806 excess deaths, COVID-19 codes were reported in 90% of death certificates. The percentage increase in pulmonary embolism-related deaths was 27% (95%CI 19-35%), 1018 deaths during the year 2020, compared to 804 mean annual deaths in the period 2018-2019. This was more evident among men, who experience an absolute increase of 147 deaths (+45%), than in women (+67 deaths; +14%). The increase was primarily driven by deaths recorded during the second wave (+91% in October-December). An excess of deaths, particularly among men and during the second wave, was also observed for other cardiovascular diseases, notably hypertensive disease, atrial fibrillation, cerebrovascular disease, and ischemic heart disease., Conclusions: We observed a considerable increase of all-cause mortality during the year 2020. This was mainly driven by COVID-19 and its complications. The relative increase in the number of pulmonary embolism-related deaths was more prominent during the second wave, suggesting a possible underdiagnosis during the first wave., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
7. Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmOnary hyPertension rEgistry (HOPE).
- Author
-
Farmakis IT, Karyofyllis P, Frantzeskaki F, Demerouti E, Anthi A, Arvanitaki A, Pitsiou G, Naka KK, Bechlioulis A, Thomaidi A, Avgeropoulou A, Brili S, Mitrouska I, Manginas A, Orfanos SE, Tsangaris I, and Giannakoulas G
- Subjects
- Chronic Disease, Humans, Incidence, Registries, COVID-19 complications, COVID-19 epidemiology, Hypertension, Pulmonary complications, Hypertension, Pulmonary epidemiology, Pulmonary Arterial Hypertension, Pulmonary Embolism complications, Pulmonary Embolism epidemiology, Pulmonary Embolism therapy
- Abstract
Competing Interests: Conflict of interest The authors do not declare any conflict of interest related to this manuscript.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.